Allergic Asthma Clinical Trial
Official title:
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
To study the effects of 1200mg gamma tocopherol, a form of vitamin E, given daily on the response of the airway in mild asthmatics after exposure to ozone (O3)
Allergic asthma (AA) is the most commonly encountered respiratory disease in children and
adults in the United States and is a leading cause of morbidity worldwide. Among the most
disruptive expressions of disease in AA is acute asthma exacerbation. The Center for Disease
Control (CDC) lists ambient air pollutants and environmental tobacco smoke as among the most
common triggers for acute asthma exacerbation. Ozone (O3) is the most commonly encountered
ambient air pollutant in the US.
Increased oxidative stress and decreased antioxidant capability have been observed in
asthmatics. These pollutants are pro-inflammatory and are associated with increased oxidative
stress, which would exacerbate reactive oxygen and reactive nitrogen species (ROS and
RNS)-induced injury in asthmatics. O3 injures epithelial cells, releasing secondary mediators
which activate inflammatory cells, in part by ligation of Toll-like receptor 4 (TLR4), the
primary receptor for lipopolysaccharide (LPS). TLR4 activation of inflammatory cells
activates (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and induces
oxidative stress. O3 and LPS has been associated with exacerbation of asthma, and the
investigators have reported that O3 and LPS augments allergic airway inflammation in allergic
asthmatics (AA). Development of interventions to mitigate these responses will greatly
decrease disease morbidity. Given the role that oxidants play in the pathophysiology of
asthma exacerbation, defects in antioxidant levels would increase risk for acute asthma
exacerbation. Nutritional deficiencies in vitamin E, ascorbate and selenium have been linked
to asthma severity, and asthmatics have decreased antioxidant levels in airway fluid. It has
been shown that vitamins C and E are decreased in airway fluids of asthmatics. Additionally,
genetic factors may increase risk for oxidant induced exacerbation of asthma. Many
investigators have reported that persons who are homozygous for the null polymorphism of the
Glutathione-S-Transferase Mu1 (GSTM1) gene and unable to produce GSTM1 protein (the GSTM1
null genotype) have increased risk of acute pollutant-induced exacerbation of asthma. This
lab has shown in healthy volunteers that the GSTM1 null genotype is associated with increased
inflammatory response to O3, with no impact on the nociceptive response to this pollutant.
Other researchers have shown that the GSTM1 null genotype is associated with increased
response to secondhand tobacco smoke, diesel exhaust, and other particulate matter
components. Romieu et al demonstrated that children with asthma in Mexico City had increased
susceptibility to O3-induced exacerbations if they had the GSTM1 null genotype. This group
also found that GSTM1 null AAs selectively benefited from antioxidant intervention. The GSTM1
null genotype is found in 20-40% of the population, and may be overrepresented in allergic
populations. Taken together, these observations show that the sizable GSTM1 null population
is at risk for pollutant-induced airway disease, and that antioxidant intervention targeting
the action of ROS and RNS will benefit asthmatics and especially GSTM1 null asthmatics.
A non-exclusive list of proposed antioxidants includes radical scavengers such as ascorbate,
a-tocopherol (aT), y-tocopherol (γT) or inducers of Nuclear factor erythroid-2-related factor
2 (NRF2), which activate NRF2 with subsequent broad upregulation of acute phase II and
antioxidant proteins. These agents are available in naturally occurring foods and as
nutritional supplements. A number of animal, cell culture and epidemiological studies support
the idea that antioxidant supplementation is useful in allergic airway disease. However,
despite these studies and widespread public and scientific enthusiasm regarding use of such
agents in asthmatics, there are scant human data to support or refute the use of such
interventions for either acute or chronic allergic airways disease.
Gamma tocopherol has both radical scavenging and anti-inflammatory actions which may play
important roles in decreasing pollutant-induced and allergic injury to the airway. Like other
isoforms of vitamin E, γT is a potent ROS scavenger and is also a powerful nucleophile that
traps electrophiles such as peroxynitrite in lipophilic compartments. One mechanism by which
γT is cytoprotective is scavenging of RNS at the un-substituted C-5 position on the
hydroxy-chroman ring of γT to form 5-NO-γ-tocopherol (5-NO-γT). Overall, vitamin E provides
general protection of DNA, lipids and proteins from radical stress. An example of such
protection is shown in rodent studies of prostate cancer in which intake of γT is associated
with decreased DNA methylation of CpG rich regions of the NRF2. NRF2 is a master regulator of
numerous cytoprotective antioxidant enzymes.
Supplementation with γT also prevents protein nitration and attenuates loss of plasma vitamin
C in plasma in a rodent peritonitis model of inflammation. The investigators have also shown
that γT inhibits Cyclooxygenase (COX)-2 and 5-Lipoxygenase (LO) in LPS-stimulated macrophages
and interleukin (IL)-1b stimulated epithelial cells. These actions are mediated primarily by
the γT metabolite 2, 7, 8-trimethyl-2S-(.-carboxyethyl)-6-hydroxychroman (γ-CEHC) which
requires hydroxylation of the γ-methyl group of γT by cytochrome P450 (CYP450). In
carrageenan- induced inflammation in male Wistar rats, γT decreases prostaglandin (PGE2) and
leukotriene (LTB4) production, suggesting that LO-mediated production of leukotrienes may
also be inhibited by γT. Tocopherols, including γT, also modulate gene expression of a number
of inflammatory genes. Thus, γT and other tocopherols decrease production of a number of
pro-inflammatory cytokines at the transcriptional level.
In animals, it has also been shown that gamma tocopherol reduces baseline eosinophilia in the
airway. In early phase I studies of gamma tocopherol-enriched mixed tocopherols (γT-mT) the
investigators have shown that γT-mT inhibits monocyte induced cytokine production, decreases
baseline nitrosative stress, and inhibits LPS eosinophil and neutrophil influx in healthy
volunteers.
SUMMARY:
There is widespread opinion that antioxidant nutrients like gamma tocopherol ( γT, a form of
Vitamin E) are an untapped and inexpensive intervention for environmentally triggered acute
asthma. However, there is a crucial gap in evidence-based support of such interventions in
asthma. A lack of coordinated research assessing specific antioxidant regimens from
preclinical, phase I and phase II studies impedes development of phase III antioxidant trials
in asthmatic populations. It is also unclear which physiological endpoints are most relevant
in such studies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
Completed |
NCT00999466 -
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
|
Phase 2 | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|
||
Withdrawn |
NCT04401631 -
Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation
|